Back to searchBackground Papers8
Result Papers0
Derived Papers0
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
NCT05156450
PHASE2INTERVENTIONAL
West China Hospital
30 participants
Started 2022-01-01 · Completed 2024-01-01
Status: Unknown (as of 12-23-2025)
Conditions
Prostatic Neoplasms, Castration-ResistantDrug Therapy, Combination
Linked Papers (from SciSciNet-V2)
Total Papers5
Background
4Result
0Derived
0Unknown
1Total Citations Per Year
Brief Summary
This is a phase Ib/II clinical study of TQB3616 capsules in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer, to determine the dose for further clinical studies and to evaluate the safety and efficacy of this combined therapy.
Sort by:
Background Papers8
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
2017
238 citations
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
2017
238 citations
Targeting cell cycle and hormone receptor pathways in cancer
2013
108 citations
Targeting cell cycle and hormone receptor pathways in cancer
2013
108 citations
Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects
2018
41 citations
Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects
2018
41 citations
<p>Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer</p>
2020
21 citations
<p>Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer</p>
2020
21 citations
Result Papers0
No result papers linked
Derived Papers0
No derived papers linked